This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
The below stocks have been identified as having potential to register bigger than normal share price moves (up or down) today based on the news cited
BP (BP.L) – Underlying replacement cost profit of $3.2bn, down from $4.2bn, ahead consensus forecast of $3.1bn. Said it would raise its quarterly dividend to 9.75 cents p/sh, 8.3% higher than a year earlier. Closing Price 488.35p (Reuters)
Foxtons Group (FOXT.L) – Q1 revenue rose 19.2% to £34.1m, property sales commissions were £17.6m, up 41.1% on prior year driven by significant volume growth in branches. Closing Price 320.20p (Reuters)
Redrow (RDW.L) – Net reservations for 17 week period were up 17% at 1,280 (1,091 in 2013) Average selling price £289k up 16%, expects good progress Closing Price 278.50p (Reuters)
Serco (SRP.L) – Warned it could downgrade its profit expectations and was considering issuing new shares to shore up its finances after its performance this year had been worse than expected. Closing Price 404.50p (Reuters)
Shire (SHP.L) – Allergan Inc. is preparing to approach Shire again with a potential takeover offer after being rebuffed in recent months, people familiar with the matter said on Monday. Closing Price 3286.00p (Reuters)
Whitbread (WTB.L) – Posted a better-than-expected 16.5% rise in full-year profit on Tuesday and said trading in the first two months of its new year had started well. Closing Price 4061.00p (Reuters)
For more information on any of these individual news items, call into the trading floor
| Stock | Code | Close | High | Low |
| AstraZeneca | AZN.L | 14.38% | 17.56% | 11.76% |
| Ladbrokes | LAD.L | 4.61% | 5.91% | -0.29% |
| William Hill | WHM.L | 2.38% | 3.15% | -0.09% |
| Premier Oil | PMO.L | 0.83% | 1.35% | -2.45% |
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance. Prepared by Michael van Dulken, Head of Research